Medytox Unveils New Toxin Formulation Lineup for the First Time at the International Society of Aesthetic Plastic Surgery Conference

Jung Hyun-ho, CEO of Medytox, is giving a presentation at a discussion session held on the 31st of last month (local time) at the International Master Course on Aging Science (IMCAS World Congress 2025). Photo by Medytox

Biopharmaceutical company Medytox announced on the 5th that it unveiled its newly developed toxin formulation lineup for the first time at IMCAS (International Master Course on Aging Science), the world's largest aesthetic surgery conference held in Paris, France, over three days until the 1st (local time).

At the special botulinum toxin session held on the last day of IMCAS, Dr. Sujeong Heo of Bundang Skin Young Clinic presented the lecture titled "Botulinum Toxin Formulation Pipeline and Future," revealing the development status of the prefilled syringe (PFS) type toxin formulation 'PF30' and the recombinant toxin formulation 'MT951.' The session was attended by eight leading global toxin companies including AbbVie and Allergan, with Medytox and Zetema being the only domestic companies participating.

'PF30' is an upgraded product of the non-animal-derived liquid botulinum toxin formulation 'MT10109L' (generic name NivobotulinumtoxinA) in PFS form, which the company expects will dramatically improve procedural convenience and accuracy. The concurrently unveiled 'MT951' is a next-generation toxin formulation developed through genetic recombination, which the company emphasized showed approximately 30% longer-lasting effects compared to other companies' toxin formulations in non-clinical trials.

Additionally, at the 'La Tribune' session where Medytox CEO Hyunho Jung participated as a panelist, a presentation was made on the overseas expansion strategy, including the launch plan for the liquid botulinum toxin formulation 'MT10109L' ahead of its entry into the U.S. market.

MT10109L is a liquid toxin formulation that excludes the use of animal-derived components throughout the entire manufacturing process, including strain cultivation and bulk production, and does not use human serum albumin (HSA) as an excipient, thereby fundamentally eliminating the risk of animal-derived viral infections.

CEO Jung stated, "MT10109L will enter the U.S. market and simultaneously expand into other countries such as Europe."

This content was produced with the assistance of AI translation services.